Morgan Stanley analyst Vikram Purohit assumed coverage of Disc Medicine (IRON) with an Overweight rating and $85 price target The potentially faster than expected path for bitopertin to market in erythropoietic protoporphyria is a clear positive, and DISC-0974 and DISC-3405 represent intriguing upside drivers ahead of key data in the second half of 2025 and 2026, the analyst tells investors in a research note.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on IRON:
- Disc Medicine price target raised to $75 from $73 at Scotiabank
- Disc Medicine’s Strategic Advancements and Promising Pipeline Drive Buy Rating
- Promising Prospects for Disc Medicine: Buy Rating Backed by Bitopertin’s Potential and Strong Financial Health
- Disc Medicine’s 2024 Financial Results and Clinical Progress
- Disc Medicine: Strong Financial and Clinical Position Supports Buy Rating